Daraxonrasib in previously treated advanced RAS-Mutated pancreatic Cancer (Registro nro. 22928)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03071nam a2200325 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260903144909.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Wolpin, Brian M. |
| Rol del Autor | Autor |
| 9 (RLIN) | 54562 |
| 245 ## - Titulo | |
| Titulo | Daraxonrasib in previously treated advanced RAS-Mutated pancreatic Cancer |
| 300 ## - Páginas | |
| Paginación | páginas: 1790-1802 |
| 520 ## - Resumen | |
| Resumen | Background: Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating RAS mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate–bound mutant and wild-type RAS. Methods: In this phase 1–2 study, we evaluated daraxonrasib in patients with advanced solid tumors with activating RAS mutations. Patients received 10 to 400 mg of daraxonrasib orally once daily; 300 mg was selected as the phase 3 dose. The primary end point was safety. Pharmacokinetics and antitumor activity were secondary end points. This report focuses on the 168 study patients with previously treated RAS-mutated PDAC. Results: Among the 168 patients with PDAC who received daraxonrasib at a dose of 300 mg or less, treatment-related adverse events of any grade were reported in 96%; such events of grade 3 or higher were reported in 30%. Treatment-related adverse events that occurred in at least 10% of the patients included rash, diarrhea, nausea, stomatitis or mucositis, vomiting, and fatigue. In a subgroup of 26 patients with RAS G12 mutations who were treated with second-line daraxonrasib at a dose of 300 mg, an objective response to therapy was reported in 35% (95% confidence interval [CI], 17 to 56). The median duration of response was 8.2 months (95% CI, 3.8 to not evaluable), with median values of 8.5 months for progression-free survival and 13.1 months for overall survival. Among the 38 patients with RAS G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival. Conclusions: Daraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated RAS-mutated PDAC; antitumor activity was also reported. <br/><br/> |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÁNCER |
| 9 (RLIN) | 1231 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | CÁNCER DEL TRACTO GASTROINTESTINAL |
| 9 (RLIN) | 53776 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | GASTROENTEROLOGÍA |
| 9 (RLIN) | 12562 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | HEMATOLOGÍA |
| 9 (RLIN) | 7422 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | ONCOLOGÍA |
| 9 (RLIN) | 12240 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | GENÉTICA GENERAL |
| 9 (RLIN) | 54107 |
| 700 ## - Autor Personal | |
| Autor Personal | Park, Wungki |
| 9 (RLIN) | 54563 |
| 700 ## - Autor Personal | |
| Autor Personal | Garrido-Laguna, Ignacio |
| 9 (RLIN) | 54564 |
| 700 ## - Autor Personal | |
| Autor Personal | Spira, Alexander |
| 9 (RLIN) | 54565 |
| 700 ## - Autor Personal | |
| Autor Personal | Starodub, Alexander |
| 9 (RLIN) | 54566 |
| 700 ## - Autor Personal | |
| Autor Personal | Sommerhalder, David |
| 9 (RLIN) | 54567 |
| 700 ## - Autor Personal | |
| Autor Personal | Punekar, Salman R. |
| 9 (RLIN) | 54568 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22676 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM015 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-08-31 |
| Catalogador | sqb |
No hay ítems disponibles.